April 25, 2025 a 01:00 pm
REGN: Fundamental Ratio Analysis - Regeneron Pharmaceuticals, Inc.
The stock of Regeneron Pharmaceuticals, Inc., trading under the ticker REGN, presents a compelling proposition in the biotech sector. Known for its innovative strides in medicine, particularly with popular products like EYLEA and Dupixent, REGN offers a robust portfolio putting it in a favorable position. Keeping an eye on their strategic partnerships and extensive pipeline could be key for prospective investors.
Fundamental Rating
Regeneron holds a strong fundamental rating, marked by high performance in discounted cash flow and return on assets. While the price-to-earnings metric suggests a moderate valuation, the company's overall score reflects steady prospects.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 4 | |
| Return on Assets | 5 | |
| Debt to Equity | 3 | |
| Price to Earnings | 2 | |
| Price to Book | 3 |
Historical Rating
Recent evaluations reveal consistent scores, with high marks for discounted cash flow and return on assets. Compared to the past, Regeneron's scores have maintained their strength, indicating stable financial health.
| Date | Overall Score | Discounted Cash Flow | Return on Equity | Return on Assets | Debt to Equity | Price to Earnings | Price to Book |
|---|---|---|---|---|---|---|---|
| 2025-04-24 | 4 | 5 | 4 | 5 | 3 | 2 | 3 |
| N/A | 0 | 5 | 4 | 5 | 3 | 2 | 3 |
Analyst Price Targets
Analysts provide an optimistic outlook with Regeneron, placing the stock's price target between $695 and $1,195. The median estimate suggests a solid potential for appreciation.
| High | Low | Median | Consensus |
|---|---|---|---|
| $1,195 | $695 | $891.5 | $948.83 |
Analyst Sentiment
With a consensus leaning towards "Buy," Regeneron has garnered favor among analysts. The overwhelming majority are inclined to purchase, reflecting confidence in the company's trajectory.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 34 | |
| Hold | 11 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Regeneron Pharmaceuticals, Inc. emerges as a leading force in the biotech arena, supported by strong product lines and promising financial metrics. While its price-to-earnings ratio suggests caution, the extensive analyst "Buy" sentiment underscores faith in its growth potential. The existing industry partnerships further enhance its outlook. Investors should consider Regeneron's balanced risk-reward profile.